ArticlePloS one2026
Integrative bioinformatics analysis identifies gut microbiota-derived metabolite-associated immune candidate targets in high-risk primary biliary cholangitis.
Article in PloS one, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveThis study aimed to identify and prioritize gut microbiota-derived metabolite-associated host candidate targets in high-risk primary biliary cholangitis (PBC) through integrative multi-omics analysis and external validation.
methodsDifferentially expressed genes between high-risk and low-risk PBC liver samples were identified using GSE79850. Gut microbiota-derived metabolite-host gene associations and PBC-related targets were obtained from gutMGene and the Open Targets Platform, respectively. Candidate genes were identified through integrative intersection analysis and ranked using an exploratory priority score. Human Liver Cell Atlas-based reference localization, immune signature analysis, and external validation using GSE119600 were performed to further characterize the candidate genes.
resultsA total of 163 differentially expressed genes were identified in GSE79850. Integrative analysis with gutMGene and the Open Targets Platform identified six core candidate genes: CCL2, CDKN1A, BCL2, CD44, FOS, and MAPK3. CCL2 showed the highest priority score, was associated with multiple gut microbiota-related metabolites, including acetate, butyrate, propionate, and succinate, and was significantly upregulated in high-risk PBC liver samples. Human Liver Cell Atlas-based reference localization showed that CCL2 was mainly distributed in immune-related cell populations, including macrophages and monocyte-derived cells. High-risk PBC samples exhibited increased chemokine signaling signature scores, and CCL2 expression was positively correlated with this signature. In the GSE119600 cohort, CD44, FOS, and CDKN1A were significantly upregulated in PBC samples compared with controls.
conclusionThis integrative analysis identified six candidate host targets associated with high-risk PBC. CCL2 showed the most convergent evidence within the discovery framework and may represent a chemokine-related hepatic microenvironment-associated candidate target. In contrast, CD44, FOS, and CDKN1A showed supportive expression patterns in the GSE119600 blood cohort. These findings represent exploratory candidate prioritization, and further validation in independent liver tissue cohorts and experimental studies is warranted.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.